Cite

    Roblin, X., Marotte, H., Leclerc, M., Del Tedesco, E., Phelip, J., Peyrin-Biroulet, L., & Paul, S. (n.d.). combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease. Journal of Crohn's and colitis, 9, 525–531. http://access.bl.uk/ark:/81055/vdc_100097085748.0x00000d